KR20230038485A - Sars-cov-2 저해제 - Google Patents
Sars-cov-2 저해제 Download PDFInfo
- Publication number
- KR20230038485A KR20230038485A KR1020237001812A KR20237001812A KR20230038485A KR 20230038485 A KR20230038485 A KR 20230038485A KR 1020237001812 A KR1020237001812 A KR 1020237001812A KR 20237001812 A KR20237001812 A KR 20237001812A KR 20230038485 A KR20230038485 A KR 20230038485A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- seq
- polypeptide
- acid sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051474P | 2020-07-14 | 2020-07-14 | |
| US63/051,474 | 2020-07-14 | ||
| US202063067593P | 2020-08-19 | 2020-08-19 | |
| US63/067,593 | 2020-08-19 | ||
| PCT/US2021/034069 WO2022015418A1 (en) | 2020-07-14 | 2021-05-25 | Sars-cov-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230038485A true KR20230038485A (ko) | 2023-03-20 |
Family
ID=76808129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237001812A Pending KR20230038485A (ko) | 2020-07-14 | 2021-05-25 | Sars-cov-2 저해제 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230250134A1 (https=) |
| EP (1) | EP4182027A1 (https=) |
| JP (2) | JP2023542453A (https=) |
| KR (1) | KR20230038485A (https=) |
| CN (1) | CN116209672A (https=) |
| AU (1) | AU2021308208A1 (https=) |
| WO (1) | WO2022015418A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024263019A1 (ko) * | 2023-06-20 | 2024-12-26 | 주식회사 엔큐라젠 | Sars-cov-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240309059A1 (en) * | 2021-07-07 | 2024-09-19 | National University Corporation Tokyo Medical And Dental University | Peptide having anti-viral activity, anti-viral agent comprising said peptide, and method for producing said anti-viral agent |
| WO2025101453A1 (en) * | 2023-11-07 | 2025-05-15 | University Of Washington | De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1 |
| WO2025221716A1 (en) * | 2024-04-17 | 2025-10-23 | University Of Washington | Smart mhc: a de-novo designed platform for soluble expression of peptide-receptive class-i mhc in e. coli |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098448A1 (en) * | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
| KR20230017215A (ko) * | 2020-05-27 | 2023-02-03 | 유니버시티 오브 워싱턴 | 드 노보 설계한 단백질 스위치에 기반한 모듈형의 일반화 가능한 바이오센서 플랫폼 |
-
2021
- 2021-05-25 EP EP21739198.6A patent/EP4182027A1/en active Pending
- 2021-05-25 KR KR1020237001812A patent/KR20230038485A/ko active Pending
- 2021-05-25 CN CN202180049677.2A patent/CN116209672A/zh active Pending
- 2021-05-25 AU AU2021308208A patent/AU2021308208A1/en active Pending
- 2021-05-25 WO PCT/US2021/034069 patent/WO2022015418A1/en not_active Ceased
- 2021-05-25 JP JP2023502638A patent/JP2023542453A/ja active Pending
- 2021-05-25 US US18/004,545 patent/US20230250134A1/en active Pending
-
2025
- 2025-08-19 JP JP2025136537A patent/JP2025170319A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024263019A1 (ko) * | 2023-06-20 | 2024-12-26 | 주식회사 엔큐라젠 | Sars-cov-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021308208A1 (en) | 2023-01-05 |
| JP2023542453A (ja) | 2023-10-10 |
| US20230250134A1 (en) | 2023-08-10 |
| CN116209672A (zh) | 2023-06-02 |
| JP2025170319A (ja) | 2025-11-18 |
| EP4182027A1 (en) | 2023-05-24 |
| WO2022015418A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230038485A (ko) | Sars-cov-2 저해제 | |
| Heaton et al. | In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies | |
| Gaillard et al. | A short double-stapled peptide inhibits respiratory syncytial virus entry and spreading | |
| EP3022298B1 (en) | Attenuated influenza vaccines and uses thereof | |
| KR102508238B1 (ko) | 코로나바이러스 감염증１９의 치료제로서 ａｃｅ２의 용도 | |
| CN103451158B (zh) | 用于犬科动物中呼吸系统疾病控制的物质和方法 | |
| KR20220147121A (ko) | 가용성 ace2 및 융합 단백질, 및 이의 응용 | |
| US20230346919A1 (en) | Sars cov-2 vaccines and high throughput screening assays based on vesicular stomatitis virus vectors | |
| CN101472606A (zh) | 用于治疗黄病毒感染的方法、分子及用途 | |
| CN101563361A (zh) | 能够感染犬科动物的流感病毒及其用途 | |
| Choi et al. | Cross-protection against MERS-CoV by prime-boost vaccination using viral spike DNA and protein | |
| Evans et al. | Benzimidazole analogs inhibit respiratory syncytial virus G protein function | |
| WO2023036209A1 (zh) | 一种复制缺陷型耐药流感病毒及其核酸节段重组率检测方法 | |
| AU2022346446A1 (en) | Multivalent polypeptide constructs capable of binding viral spike proteins and methods of using the same | |
| Wang et al. | Substitution of S179P in the lyssavirus phosphoprotein impairs its interferon antagonistic function | |
| WO2015057966A2 (en) | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV) | |
| CA3181996A1 (en) | Sars-cov-2 inhibitors | |
| WO2026021236A1 (zh) | 可抑制类mers冠状病毒感染的多肽及其应用 | |
| Singh et al. | A recent update on SARS-CoV-2 transmission and its variants: transmission, pathogenic mechanism, and treatment | |
| CN102741277A (zh) | 在治疗运动神经元疾病中的IFNγ抑制剂 | |
| US20070161550A1 (en) | Antiviral compositions which inhibit paramyxovirus infection | |
| Case et al. | Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice | |
| CN117043176A (zh) | 抗感染双环肽配体 | |
| CN116888139A (zh) | 诱导高水平i型干扰素的新型复制缺陷型甲型流感病毒 | |
| Sun et al. | Characterization of the Pathogenic Features of Multiple SARS‐CoV‐2 Pandemic Strains in Different Mouse Models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230116 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20240524 Comment text: Request for Examination of Application |